CA2311409A1 - Treatment with anti-erbb2 antibodies - Google Patents
Treatment with anti-erbb2 antibodies Download PDFInfo
- Publication number
- CA2311409A1 CA2311409A1 CA002311409A CA2311409A CA2311409A1 CA 2311409 A1 CA2311409 A1 CA 2311409A1 CA 002311409 A CA002311409 A CA 002311409A CA 2311409 A CA2311409 A CA 2311409A CA 2311409 A1 CA2311409 A1 CA 2311409A1
- Authority
- CA
- Canada
- Prior art keywords
- cancer
- erbb2
- antibody
- article
- manufacture
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Abstract
The present invention concerns the treatment of disorders characterized by the overexpression of ErbB2. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer overexpressing ErbB2 with a combination of an anti-ErbB2 antibody and a chemotherapeutic agent other than an anthracycline, e.g. doxorubicin or epirubicin.
Claims (19)
1. A method for the treatment of a human patient susceptible to or diagnosed with a disorder characterized by overexpression of ErbB2 receptor, comprising administering an effective amount of a combination of an anti-ErbB2 antibody and a chemotherapeutic agent other than an anthracycline derivative, in the absence of an anthracycline derivative, to the human patient.
2. The method of claim 1 wherein said disorder is a benign or malignant tumor.
3. The method of claim 1 wherein said disorder is a cancer.
4. The method of claim 3 wherein said cancer is selected from the group consisting of breast cancer, squamous cell cancer, small-cell lung cancer, non-small cell lung cancer, gastrointestinal cancer, pancreatic cancer, glioblastoma, cervical cancer, ovarian cancer, liver cancer, bladder cancer, hepatoma, colon cancer, colorectal cancer, endometrial carcinoma, salivary gland carcinoma, kidney cancer, liver cancer, prostate cancer, vulval cancer, thyroid cancer, hepatic carcinoma and various types of head and neck cancer.
5. The method of claim 4 wherein said cancer is breast cancer.
6. The method of claim 5 wherein said cancer is metastatic breast carcinoma.
7. The method of claim 1 wherein said antibody binds to the extracellular domain of the ErbB2 receptor.
8. The method of claim 7 wherein said antibody binds to epitope 4D5 within the ErbB2 extracellular domain sequence.
9. The method of claim 8 wherein said antibody is a humanized 4D5 anti-ErbB2 antibody.
10. The method of claim 1 wherein said chemotherapeutic agent is a taxoid.
11. The method of claim 10 wherein said taxoid is paclitaxel or doxetaxel.
12. The method of claim 1 wherein the effective amount of said combination is lower than the sum of the effective amounts of said anti-ErbB2 antibody and said chemotherapeutic agent, when administered individually, as single agents.
13. The method of claim 1 wherein efficacy is measured by determining the time to disease progression or the response rate.
14. An article of manufacture, comprising a container, a composition within the container comprising an anti-ErbB2 antibody, and a package insert containing instructions to avoid the use of anthracycline-type chemotherapeutics in combination with said composition.
15. The article of manufacture of claim l4 further comprising a label on or associated with the container that indicates that said composition can be used for treating a condition characterized by overexpression of ErbB2 receptor.
16. The article of manufacture of claim 15 wherein said label indicates that said composition can be used for the treatment of breast cancer.
17. The article of manufacture of claim 15 wherein said anti-ErbB2 antibody binds to the extracellular domain of the receptor.
18. The article of manufacture of claim 17 wherein said anti-ErbB2 antibody binds to epitope 4D5 within the ErbB2 extracellular domain sequence.
19. The article of manufacture of claim 18 wherein said antibody is a humanized 4D5 anti-ErbB2 antibody.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA2730373A CA2730373A1 (en) | 1997-12-12 | 1998-12-10 | Treatment of cancer having overexpression of erbb2 with anti-erbb2 antibodies and a hormonal chemotherapeutic agent |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US6934697P | 1997-12-12 | 1997-12-12 | |
US60/069,346 | 1997-12-12 | ||
PCT/US1998/026266 WO1999031140A1 (en) | 1997-12-12 | 1998-12-10 | TREATMENT WITH ANTI-ErbB2 ANTIBODIES |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2730373A Division CA2730373A1 (en) | 1997-12-12 | 1998-12-10 | Treatment of cancer having overexpression of erbb2 with anti-erbb2 antibodies and a hormonal chemotherapeutic agent |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2311409A1 true CA2311409A1 (en) | 1999-06-24 |
CA2311409C CA2311409C (en) | 2011-04-12 |
Family
ID=22088358
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2311409A Expired - Lifetime CA2311409C (en) | 1997-12-12 | 1998-12-10 | Treatment with anti-erbb2 antibodies |
CA2730373A Abandoned CA2730373A1 (en) | 1997-12-12 | 1998-12-10 | Treatment of cancer having overexpression of erbb2 with anti-erbb2 antibodies and a hormonal chemotherapeutic agent |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2730373A Abandoned CA2730373A1 (en) | 1997-12-12 | 1998-12-10 | Treatment of cancer having overexpression of erbb2 with anti-erbb2 antibodies and a hormonal chemotherapeutic agent |
Country Status (18)
Country | Link |
---|---|
US (11) | US7846441B1 (en) |
EP (3) | EP1037926B1 (en) |
JP (7) | JP2002508397A (en) |
KR (7) | KR20010033019A (en) |
CN (2) | CN1820734B (en) |
AR (1) | AR020051A1 (en) |
AU (1) | AU1908199A (en) |
BR (1) | BR9815363A (en) |
CA (2) | CA2311409C (en) |
DK (1) | DK1037926T3 (en) |
ES (1) | ES2450922T3 (en) |
HK (2) | HK1030784A1 (en) |
IL (4) | IL136201A0 (en) |
NO (2) | NO20002957L (en) |
NZ (1) | NZ504597A (en) |
TR (1) | TR200001689T2 (en) |
WO (1) | WO1999031140A1 (en) |
ZA (1) | ZA9811162B (en) |
Families Citing this family (101)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2697752B1 (en) | 1992-11-10 | 1995-04-14 | Rhone Poulenc Rorer Sa | Antitumor compositions containing taxane derivatives. |
US6524832B1 (en) | 1994-02-04 | 2003-02-25 | Arch Development Corporation | DNA damaging agents in combination with tyrosine kinase inhibitors |
US6972170B1 (en) | 1997-12-01 | 2005-12-06 | Sloan-Kettering Institute For Cancer Research | Markers for prostate cancer |
ZA9811162B (en) * | 1997-12-12 | 2000-06-07 | Genentech Inc | Treatment with anti-ERBB2 antibodies. |
US6417168B1 (en) | 1998-03-04 | 2002-07-09 | The Trustees Of The University Of Pennsylvania | Compositions and methods of treating tumors |
US6333348B1 (en) | 1999-04-09 | 2001-12-25 | Aventis Pharma S.A. | Use of docetaxel for treating cancers |
US6316462B1 (en) | 1999-04-09 | 2001-11-13 | Schering Corporation | Methods of inducing cancer cell death and tumor regression |
ATE415979T1 (en) * | 1999-05-14 | 2008-12-15 | Genentech Inc | TREATMENT WITH ANTI-ERBB2 ANTIBODIES |
EP1208232A4 (en) * | 1999-06-10 | 2003-01-15 | Sloan Kettering Inst Cancer | Markers for prostate cancer |
DK1189634T3 (en) * | 1999-06-25 | 2007-06-25 | Genentech Inc | Treatment of prostate cancer with anti-ErbB2 antibodies |
US20040013667A1 (en) * | 1999-06-25 | 2004-01-22 | Genentech, Inc. | Treatment with anti-ErbB2 antibodies |
US6949245B1 (en) | 1999-06-25 | 2005-09-27 | Genentech, Inc. | Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies |
SI2803367T1 (en) * | 1999-06-25 | 2018-04-30 | Immunogen, Inc. | Methods of treatment using anti-ERBB antibody-maytansinoid conjugates |
CN100340575C (en) * | 1999-06-25 | 2007-10-03 | 杰南技术公司 | Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies |
US20030086924A1 (en) * | 1999-06-25 | 2003-05-08 | Genentech, Inc. | Treatment with anti-ErbB2 antibodies |
ATE330967T1 (en) | 1999-07-02 | 2006-07-15 | Genentech Inc | PEPTIDE COMPOUNDS BINDING TO HER2 |
GB9917012D0 (en) * | 1999-07-20 | 1999-09-22 | Pharmacia & Upjohn Spa | Combined preparations comprising antitumor agents |
JP2003505432A (en) | 1999-07-23 | 2003-02-12 | グラクソ グループ リミテッド | Combination of anti-EP-CAM antibody and chemotherapeutic agent |
WO2001008636A2 (en) * | 1999-08-03 | 2001-02-08 | The Ohio State University | Polypeptides and polynucleotides for enhancing immune reactivity to her-2 protein |
DK1210115T3 (en) * | 1999-08-27 | 2009-11-30 | Genentech Inc | Dosages for treatment with anti-ErB2 antibodies |
CA2385528C (en) | 1999-10-01 | 2013-12-10 | Immunogen, Inc. | Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents |
AU3458401A (en) | 2000-01-25 | 2001-08-07 | Genentech Inc. | Compositions and methods for treatment of cancer |
US7097840B2 (en) | 2000-03-16 | 2006-08-29 | Genentech, Inc. | Methods of treatment using anti-ErbB antibody-maytansinoid conjugates |
EP1265635A1 (en) * | 2000-03-22 | 2002-12-18 | Glaxo Group Limited | Pharmaceutical comprising an agent that blocks the cell cycle and an antibody |
CA2409652A1 (en) * | 2000-05-15 | 2001-11-22 | Giorgio Massimini | Aromatase inhibitors and monoclonal anti-her2 antibodies as antitumors agents |
PL217410B1 (en) * | 2000-05-19 | 2014-07-31 | Genentech Inc | Gene detection assay for improving the likelihood of an effective response to an erbb antagonist cancer therapy |
GB0017635D0 (en) * | 2000-07-18 | 2000-09-06 | Pharmacia & Upjohn Spa | Antitumor combined therapy |
WO2002087618A1 (en) * | 2001-04-27 | 2002-11-07 | Takeda Chemical Industries, Ltd. | Preventive/therapeutic method for cancer |
US20040138160A1 (en) * | 2001-04-27 | 2004-07-15 | Kenichiro Naito | Preventive/therapeutic method for cancer |
US20040018573A1 (en) * | 2002-04-18 | 2004-01-29 | Power Scott D | Production of functional antibodies in filamentous fungi |
KR100978169B1 (en) | 2002-05-30 | 2010-08-25 | 도레이 카부시키가이샤 | Immunosuppressive substance adsorbent, extracorporeal circulation column and method of treating cancer |
AU2002951853A0 (en) * | 2002-10-04 | 2002-10-24 | Commonwealth Scientific And Industrial Research Organisation | Crystal structure of erbb2 and uses thereof |
US8088387B2 (en) | 2003-10-10 | 2012-01-03 | Immunogen Inc. | Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates |
SV2006002143A (en) * | 2004-06-16 | 2006-01-26 | Genentech Inc | USE OF AN ANTIBODY FOR THE TREATMENT OF CANCER RESISTANT TO PLATINUM |
US7560111B2 (en) | 2004-07-22 | 2009-07-14 | Genentech, Inc. | HER2 antibody composition |
JO3000B1 (en) | 2004-10-20 | 2016-09-05 | Genentech Inc | Antibody Formulations. |
CN101115849A (en) * | 2004-12-07 | 2008-01-30 | 健泰科生物技术公司 | Selecting patients for therapy with a her inhibitor |
CN102580084B (en) * | 2005-01-21 | 2016-11-23 | 健泰科生物技术公司 | The fixed dosage of HER antibody is administered |
AU2006213659A1 (en) * | 2005-02-09 | 2006-08-17 | Genentech, Inc. | Inhibiting HER2 shedding with matrix metalloprotease antagonists |
CN103251946A (en) * | 2005-02-23 | 2013-08-21 | 健泰科生物技术公司 | Extending time to disease progression or survival in cancer patients using a her dimerization inhibitor |
US20060204505A1 (en) * | 2005-03-08 | 2006-09-14 | Sliwkowski Mark X | Methods for identifying tumors responsive to treatment with HER dimerization inhibitors (HDIs) |
JP2006316040A (en) | 2005-05-13 | 2006-11-24 | Genentech Inc | Herceptin(r) adjuvant treatment |
JP5222134B2 (en) | 2005-06-15 | 2013-06-26 | ザ オハイオ ステート ユニバーシティー リサーチ ファウンデーション | HER-2 peptide |
PE20070207A1 (en) * | 2005-07-22 | 2007-03-09 | Genentech Inc | COMBINED TREATMENT OF TUMORS THAT EXPRESS HER |
EP1951754A2 (en) * | 2005-10-11 | 2008-08-06 | Domantis Limited | Antibody polypeptide library screening and selected antibody polypeptides |
TW200812615A (en) | 2006-03-22 | 2008-03-16 | Hoffmann La Roche | Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2 |
PL2056874T3 (en) | 2006-08-21 | 2013-02-28 | Hoffmann La Roche | Tumor therapy with an anti-vegf antibody |
WO2008109440A2 (en) | 2007-03-02 | 2008-09-12 | Genentech, Inc. | Predicting response to a her dimerisation inhibitor based on low her3 expression |
US8557588B2 (en) * | 2007-03-27 | 2013-10-15 | Schlumberger Technology Corporation | Methods and apparatus for sampling and diluting concentrated emulsions |
US20090304590A1 (en) * | 2007-05-29 | 2009-12-10 | Wyeth | Therapeutic compositions and methods |
US20090258005A1 (en) * | 2007-05-29 | 2009-10-15 | Trubion Pharmaceuticals Inc. | Therapeutic compositions and methods |
US9551033B2 (en) | 2007-06-08 | 2017-01-24 | Genentech, Inc. | Gene expression markers of tumor resistance to HER2 inhibitor treatment |
ES2583377T3 (en) | 2007-06-08 | 2016-09-20 | Genentech, Inc. | Gene expression markers of tumor resistance to HER2 inhibitor treatment |
ES2962777T3 (en) * | 2007-11-15 | 2024-03-21 | Amgen Inc | Antioxidant-stabilized aqueous antibody formulation for parenteral administration |
EP2235536A4 (en) | 2007-12-20 | 2011-05-04 | Lab Corp America Holdings | Her-2 diagnostic methods |
TWI472339B (en) | 2008-01-30 | 2015-02-11 | Genentech Inc | Composition comprising antibody that binds to domain ii of her2 and acidic variants thereof |
ES2342646B1 (en) * | 2008-06-02 | 2011-04-26 | Institut De Recerca Hospital Universitari Vall Hebron | METHOD OF DIAGNOSIS OF CANCERES THAT EXPRESS THE RECEIVER HER-2 OR ITS TRUNCATED VARIANTS. |
BRPI0812682A2 (en) * | 2008-06-16 | 2010-06-22 | Genentech Inc | metastatic breast cancer treatment |
AU2009308707A1 (en) * | 2008-10-31 | 2010-05-06 | Biogen Idec Ma Inc. | LIGHT targeting molecules and uses thereof |
HUE032693T2 (en) | 2008-11-22 | 2017-10-30 | Hoffmann La Roche | Use of anti-vegf antibody in combination with chemotherapy for treating breast cancer |
EP2438442B1 (en) | 2008-12-01 | 2017-08-09 | Laboratory Corporation of America Holdings | Methods and assays for measuring p95 and/or p95 complexes in a sample and antibodies specific for p95 |
JP5746051B2 (en) | 2009-01-15 | 2015-07-08 | ラボラトリー コーポレイション オブ アメリカ ホールディングス | Method for determining patient response by measuring HER-3 |
US20100234283A1 (en) | 2009-02-04 | 2010-09-16 | The Ohio State University Research Foundation | Immunogenic epitopes, peptidomimetics, and anti-peptide antibodies, and methods of their use |
MA33198B1 (en) | 2009-03-20 | 2012-04-02 | Genentech Inc | ANTI-HER DI-SPECIFIC ANTIBODIES |
SG176073A1 (en) | 2009-05-29 | 2011-12-29 | Hoffmann La Roche | Modulators for her2 signaling in her2 expressing patients with gastric cancer |
MX2012008958A (en) | 2010-02-18 | 2012-08-23 | Genentech Inc | Neuregulin antagonists and use thereof in treating cancer. |
WO2011146568A1 (en) | 2010-05-19 | 2011-11-24 | Genentech, Inc. | Predicting response to a her inhibitor |
CA2800785C (en) | 2010-05-27 | 2019-09-24 | Genmab A/S | Monoclonal antibodies against her2 |
EP2575880B1 (en) | 2010-05-27 | 2019-01-16 | Genmab A/S | Monoclonal antibodies against her2 epitope |
CN103080136B (en) | 2010-06-18 | 2015-08-12 | 霍夫曼-拉罗奇有限公司 | Anti-Axl antibody and using method |
TW201302793A (en) | 2010-09-03 | 2013-01-16 | Glaxo Group Ltd | Novel antigen binding proteins |
CN101974535B (en) * | 2010-11-03 | 2012-12-19 | 北京天广实生物技术股份有限公司 | Preparation and application of novel anti-ErbB2 humanized antibody MIL12 |
EP2643353A1 (en) | 2010-11-24 | 2013-10-02 | Novartis AG | Multispecific molecules |
EP2655413B1 (en) | 2010-12-23 | 2019-01-16 | F.Hoffmann-La Roche Ag | Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery |
US20140170149A1 (en) | 2011-04-20 | 2014-06-19 | Genmab A/S | Bispecific antibodies against her2 and cd3 |
CA2842375A1 (en) | 2011-08-17 | 2013-02-21 | Erica Jackson | Neuregulin antibodies and uses thereof |
EP2751285B2 (en) * | 2011-08-31 | 2020-04-01 | Genentech, Inc. | Method for sensitivity testing of a tumour for a egfr kinase inhibitor |
MX2014004021A (en) | 2011-10-14 | 2014-04-30 | Genentech Inc | Uses for and article of manufacture including her2 dimerization inhibitor pertuzumab. |
WO2013063229A1 (en) | 2011-10-25 | 2013-05-02 | The Regents Of The University Of Michigan | Her2 targeting agent treatment in non-her2-amplified cancers having her2 expressing cancer stem cells |
AU2012346540C1 (en) | 2011-11-30 | 2019-07-04 | Genentech, Inc. | ErbB3 mutations in cancer |
US9376715B2 (en) | 2011-12-09 | 2016-06-28 | Roche Molecular Systems, Inc | Methods for detecting mutations in the catalytic subunit of the phosphoinositol-3 kinase (PIK3CA) gene |
AU2013240261A1 (en) | 2012-03-27 | 2014-09-18 | Genentech, Inc. | Diagnosis and treatments relating to HER3 inhibitors |
US10093740B2 (en) | 2012-10-15 | 2018-10-09 | Universitat Zurich | Bispecific HER2 ligands for cancer therapy |
EP2719706A1 (en) | 2012-10-15 | 2014-04-16 | Universität Zürich | Bispecific HER2 ligands for cancer therapy |
MX363188B (en) | 2012-11-30 | 2019-03-13 | Hoffmann La Roche | Identification of patients in need of pd-l1 inhibitor cotherapy. |
EP2986643A2 (en) | 2013-04-16 | 2016-02-24 | F. Hoffmann-La Roche AG | Pertuzumab variants and evaluation thereof |
CA2908391A1 (en) | 2013-05-01 | 2014-11-06 | Five Prime Therapeutics, Inc. | Methods of treating cancer |
SG10201809411PA (en) | 2014-04-25 | 2018-11-29 | Genentech Inc | Methods of treating early breast cancer with trastuzumab-mcc-dm1 and pertuzumab |
WO2016196373A2 (en) | 2015-05-30 | 2016-12-08 | Genentech, Inc. | Methods of treating her2-positive metastatic breast cancer |
WO2017087280A1 (en) | 2015-11-16 | 2017-05-26 | Genentech, Inc. | Methods of treating her2-positive cancer |
WO2017194554A1 (en) | 2016-05-10 | 2017-11-16 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Combinations therapies for the treatment of cancer |
AU2017292934B2 (en) * | 2016-07-07 | 2024-04-04 | Bolt Biotherapeutics, Inc. | Antibody adjuvant conjugates |
TW201818940A (en) | 2016-11-04 | 2018-06-01 | 美商建南德克公司 | Treatment of HER2-positive breast cancer |
MX2019007801A (en) | 2016-12-28 | 2019-10-30 | Genentech Inc | Treatment of advanced her2 expressing cancer. |
HUE052551T2 (en) | 2017-01-17 | 2021-05-28 | Genentech Inc | Subcutaneous her2 antibody formulations |
AU2018227788B2 (en) | 2017-03-02 | 2021-04-22 | F. Hoffmann-La Roche Ag | Adjuvant treatment of HER2-positive breast cancer |
CA3059241A1 (en) | 2017-04-24 | 2018-11-01 | Genentech, Inc. | Erbb2/her2 mutations in the transmbrane or juxtamembrane domain |
JP2019043214A (en) | 2017-08-30 | 2019-03-22 | いすゞ自動車株式会社 | Steering device |
JP2022504472A (en) | 2018-10-08 | 2022-01-13 | ウニベルシテート チューリッヒ | HER2-binding tetrameric polypeptide |
WO2020190725A1 (en) | 2019-03-15 | 2020-09-24 | Bolt Biotherapeutics, Inc. | Immunoconjugates targeting her2 |
IL303350A (en) | 2020-12-04 | 2023-08-01 | Macrogenics Inc | Pharmaceutical compositions of a her2/neu antibody and use of the same |
Family Cites Families (116)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US444960A (en) * | 1891-01-20 | Fence or gate | ||
US4017471A (en) | 1975-09-15 | 1977-04-12 | G. D. Searle & Co. | Immunological compounds |
US4935341A (en) | 1986-06-04 | 1990-06-19 | Whitehead Institute For Biomedical Research | Detection of point mutations in neu genes |
US5169774A (en) | 1984-02-08 | 1992-12-08 | Cetus Oncology Corporation | Monoclonal anti-human breast cancer antibodies |
US6054561A (en) | 1984-02-08 | 2000-04-25 | Chiron Corporation | Antigen-binding sites of antibody molecules specific for cancer antigens |
US4753894A (en) | 1984-02-08 | 1988-06-28 | Cetus Corporation | Monoclonal anti-human breast cancer antibodies |
US4943533A (en) | 1984-03-01 | 1990-07-24 | The Regents Of The University Of California | Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor |
US7838216B1 (en) | 1986-03-05 | 2010-11-23 | The United States Of America, As Represented By The Department Of Health And Human Services | Human gene related to but distinct from EGF receptor gene |
US5401638A (en) | 1986-06-04 | 1995-03-28 | Oncogene Science, Inc. | Detection and quantification of neu related proteins in the biological fluids of humans |
US4994558A (en) | 1986-12-24 | 1991-02-19 | Eli Lilly And Company | Immunoglobulin conjugates |
US4968603A (en) | 1986-12-31 | 1990-11-06 | The Regents Of The University Of California | Determination of status in neoplastic disease |
US4975278A (en) | 1988-02-26 | 1990-12-04 | Bristol-Myers Company | Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells |
US5824311A (en) | 1987-11-30 | 1998-10-20 | Trustees Of The University Of Pennsylvania | Treatment of tumors with monoclonal antibodies against oncogene antigens |
US5720937A (en) | 1988-01-12 | 1998-02-24 | Genentech, Inc. | In vivo tumor detection assay |
JP3040121B2 (en) | 1988-01-12 | 2000-05-08 | ジェネンテク,インコーポレイテッド | Methods of treating tumor cells by inhibiting growth factor receptor function |
AU3568289A (en) | 1988-04-18 | 1989-11-24 | Applied Biotechnology, Inc. | Detection of neu gene expression and products |
JP2761543B2 (en) | 1988-08-17 | 1998-06-04 | 味の素株式会社 | Monoclonal antibody against human proto-oncogene product and hybridoma producing the same |
ATE155813T1 (en) | 1989-05-19 | 1997-08-15 | Genentech Inc | HER2 EXTRACELLULAR DOMAIN |
US5705157A (en) * | 1989-07-27 | 1998-01-06 | The Trustees Of The University Of Pennsylvania | Methods of treating cancerous cells with anti-receptor antibodies |
US6884418B1 (en) | 1989-08-04 | 2005-04-26 | Berlex Laboratories, Inc. | Use of ligand-mimicking agents and anti-neoplastic drugs in cancer therapy |
AU645760B2 (en) | 1989-08-04 | 1994-01-27 | Berlex Laboratories, Inc. | C-erbb-2 external domain: GP75 |
JP2895105B2 (en) | 1989-09-14 | 1999-05-24 | 株式会社ニチレイ | Serodiagnosis method for breast cancer by immunoassay of c-erbB-2 oncogene product and kit therefor |
JP3208427B2 (en) | 1989-09-29 | 2001-09-10 | オー・エス・アイ・ファーマシューテイカルズ・インコーポレイテッド | Detection and quantification of neu-related proteins in human biological fluids |
US5183884A (en) | 1989-12-01 | 1993-02-02 | United States Of America | Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor |
WO1991015230A1 (en) | 1990-04-06 | 1991-10-17 | The Trustees Of The University Of Pennsylvania | Ligand for the neu gene product |
US5578482A (en) | 1990-05-25 | 1996-11-26 | Georgetown University | Ligand growth factors that bind to the erbB-2 receptor protein and induce cellular responses |
EP0517895B1 (en) | 1990-12-14 | 1996-11-20 | Cell Genesys, Inc. | Chimeric chains for receptor-associated signal transduction pathways |
US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
US5367060A (en) | 1991-05-24 | 1994-11-22 | Genentech, Inc. | Structure, production and use of heregulin |
US5834229A (en) | 1991-05-24 | 1998-11-10 | Genentech, Inc. | Nucleic acids vectors and host cells encoding and expressing heregulin 2-α |
IL101943A0 (en) | 1991-05-24 | 1992-12-30 | Genentech Inc | Structure,production and use of heregulin |
WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
LU91067I2 (en) | 1991-06-14 | 2004-04-02 | Genentech Inc | Trastuzumab and its variants and immunochemical derivatives including immotoxins |
US6800738B1 (en) | 1991-06-14 | 2004-10-05 | Genentech, Inc. | Method for making humanized antibodies |
US5939531A (en) | 1991-07-15 | 1999-08-17 | Novartis Corp. | Recombinant antibodies specific for a growth factor receptor |
CA2096417C (en) | 1991-08-22 | 2000-10-10 | Sarah S. Bacus | Methods and compositions for cancer therapy and for prognosticating responses to cancer therapy |
US5288477A (en) | 1991-09-27 | 1994-02-22 | Becton, Dickinson And Company | Method for prognosticating response to cancer therapy |
US5587458A (en) | 1991-10-07 | 1996-12-24 | Aronex Pharmaceuticals, Inc. | Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof |
WO1993012220A1 (en) | 1991-12-12 | 1993-06-24 | Berlex Laboratories, Inc. | RECOMBINANT AND CHIMERIC ANTIBODIES TO c-erbB-2 |
DE69333807T2 (en) | 1992-02-06 | 2006-02-02 | Chiron Corp., Emeryville | MARKERS FOR CANCER AND BIOSYNTHETIC BINDEPROTEIN THEREFOR |
US5776427A (en) | 1992-03-05 | 1998-07-07 | Board Of Regents, The University Of Texas System | Methods for targeting the vasculature of solid tumors |
AU4025193A (en) | 1992-04-08 | 1993-11-18 | Cetus Oncology Corporation | Humanized C-erbB-2 specific antibodies |
ZA932522B (en) | 1992-04-10 | 1993-12-20 | Res Dev Foundation | Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens |
IT1257898B (en) * | 1992-06-16 | 1996-02-16 | PROCEDURE AND EQUIPMENT FOR THE PRODUCTION, IN PARTICULAR DOMESTIC, OF DRINKS. | |
AU687346B2 (en) | 1992-06-30 | 1998-02-26 | Oncologix, Inc. | A combination of anti-erbB-2 monoclonal antibodies and method of using |
WO1994009022A1 (en) | 1992-10-09 | 1994-04-28 | Oncor, Inc. | Methods for the detection of chromosome structural abnormalities by in situ hybridization to fixed tissue |
FR2697752B1 (en) | 1992-11-10 | 1995-04-14 | Rhone Poulenc Rorer Sa | Antitumor compositions containing taxane derivatives. |
CA2103323A1 (en) | 1992-11-24 | 1994-05-25 | Gregory D. Plowman | Her4 human receptor tyrosine kinase |
US5801005A (en) | 1993-03-17 | 1998-09-01 | University Of Washington | Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated |
US5869445A (en) | 1993-03-17 | 1999-02-09 | University Of Washington | Methods for eliciting or enhancing reactivity to HER-2/neu protein |
DK0616812T3 (en) | 1993-03-24 | 2000-04-25 | Berlex Biosciences | Combination of antihormone compounds and binding molecules to treat cancer |
AU6527894A (en) | 1993-03-30 | 1994-10-24 | Trustees Of The University Of Pennsylvania, The | Prevention of tumors with monoclonal antibodies against (neu) |
US5430620A (en) | 1993-10-08 | 1995-07-04 | Cogent Light Technologies, Inc. | Compact surgical illumination system capable of dynamically adjusting the resulting field of illumination |
US20030108545A1 (en) | 1994-02-10 | 2003-06-12 | Patricia Rockwell | Combination methods of inhibiting tumor growth with a vascular endothelial growth factor receptor antagonist |
US6811779B2 (en) | 1994-02-10 | 2004-11-02 | Imclone Systems Incorporated | Methods for reducing tumor growth with VEGF receptor antibody combined with radiation and chemotherapy |
US5837523A (en) | 1994-05-05 | 1998-11-17 | The Trustees Of The University Of Pennsylvania | Compositions and methods of treating tumors |
US5910486A (en) | 1994-09-06 | 1999-06-08 | Uab Research Foundation | Methods for modulating protein function in cells using, intracellular antibody homologues |
US5846749A (en) | 1994-10-12 | 1998-12-08 | The Regents Of The University Of California | Quantitative measurement of tissue protein identified by immunohistochemistry and standardized protein determination |
US5804396A (en) | 1994-10-12 | 1998-09-08 | Sugen, Inc. | Assay for agents active in proliferative disorders |
US6214388B1 (en) | 1994-11-09 | 2001-04-10 | The Regents Of The University Of California | Immunoliposomes that optimize internalization into target cells |
ATE170082T1 (en) | 1994-11-10 | 1998-09-15 | Univ Eberhard Karls | METHOD FOR INHIBITING THE GROWTH OF LEUKEMIC CELLS BY HER-2 PROTEIN LINES |
EP0794792A1 (en) | 1994-12-02 | 1997-09-17 | Chiron Corporation | Method of promoting an immune response with a bispecific antibody |
US5783404A (en) | 1995-04-13 | 1998-07-21 | Amgen Inc. | Methods and compositions for determining HER-2/neu expression using monoclonal antibodies |
US5663144A (en) | 1995-05-03 | 1997-09-02 | The Trustees Of The University Of Pennsylvania | Compounds that bind to p185 and methods of using the same |
JPH11507402A (en) * | 1995-05-26 | 1999-06-29 | アイジェン・インコーポレーテッド | Molecularly imprinted granular polymer and its stabilized suspension polymerization in perfluorocarbon liquid |
JP3354035B2 (en) * | 1995-05-31 | 2002-12-09 | 富士写真フイルム株式会社 | Processing method of silver halide color photographic light-sensitive material |
US6410690B1 (en) | 1995-06-07 | 2002-06-25 | Medarex, Inc. | Therapeutic compounds comprised of anti-Fc receptor antibodies |
DE69638269D1 (en) | 1995-06-14 | 2010-11-18 | Univ California | HIGH-AFFINE HUMAN ANTIBODY AGAINST TUMORANTIGENE |
US6685940B2 (en) | 1995-07-27 | 2004-02-03 | Genentech, Inc. | Protein formulation |
US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
US5783186A (en) * | 1995-12-05 | 1998-07-21 | Amgen Inc. | Antibody-induced apoptosis |
EP0894139A1 (en) | 1996-03-20 | 1999-02-03 | Board Of Regents The University Of Texas System | Sensitization of her-2/neu overexpressing cancer cells to chemotherapy |
US5925519A (en) | 1996-06-03 | 1999-07-20 | The Regents Of The University Of California | Genetic alterations associated with prostate cancer |
US5922845A (en) | 1996-07-11 | 1999-07-13 | Medarex, Inc. | Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies |
NZ519191A (en) | 1996-10-18 | 2005-04-29 | Univ Texas | Antibodies that bind to domain 1 of ErbB2 useful for inducing cell death via apoptosis, and nucleic acids encoding such antibodies |
AU5243198A (en) | 1996-10-30 | 1998-05-22 | Uab Research Foundation, The | Enhancement of tumor cell chemosensitivity and radiosensitivity using single chain intracellular antibodies |
AU737910B2 (en) | 1997-01-31 | 2001-09-06 | Regents Of The University Of California, The | Chimeric antibody fusion proteins for the recruitment and stimulation of an antitumor immune response |
US5994071A (en) | 1997-04-04 | 1999-11-30 | Albany Medical College | Assessment of prostate cancer |
ZA9811162B (en) | 1997-12-12 | 2000-06-07 | Genentech Inc | Treatment with anti-ERBB2 antibodies. |
IL138034A0 (en) | 1998-03-27 | 2001-10-31 | Genentech Inc | Apo-2 ligand-anti-her-2 antibody synergism |
CN103641885A (en) | 1998-05-06 | 2014-03-19 | 基因技术股份有限公司 | Protein purification by ion exchange chromatography |
US6316462B1 (en) | 1999-04-09 | 2001-11-13 | Schering Corporation | Methods of inducing cancer cell death and tumor regression |
US6333348B1 (en) | 1999-04-09 | 2001-12-25 | Aventis Pharma S.A. | Use of docetaxel for treating cancers |
ATE415979T1 (en) | 1999-05-14 | 2008-12-15 | Genentech Inc | TREATMENT WITH ANTI-ERBB2 ANTIBODIES |
DK1189634T3 (en) | 1999-06-25 | 2007-06-25 | Genentech Inc | Treatment of prostate cancer with anti-ErbB2 antibodies |
US7041292B1 (en) | 1999-06-25 | 2006-05-09 | Genentech, Inc. | Treating prostate cancer with anti-ErbB2 antibodies |
US20040013667A1 (en) | 1999-06-25 | 2004-01-22 | Genentech, Inc. | Treatment with anti-ErbB2 antibodies |
US20030086924A1 (en) | 1999-06-25 | 2003-05-08 | Genentech, Inc. | Treatment with anti-ErbB2 antibodies |
US6949245B1 (en) | 1999-06-25 | 2005-09-27 | Genentech, Inc. | Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies |
DK1210115T3 (en) | 1999-08-27 | 2009-11-30 | Genentech Inc | Dosages for treatment with anti-ErB2 antibodies |
US7097840B2 (en) | 2000-03-16 | 2006-08-29 | Genentech, Inc. | Methods of treatment using anti-ErbB antibody-maytansinoid conjugates |
CA2409652A1 (en) | 2000-05-15 | 2001-11-22 | Giorgio Massimini | Aromatase inhibitors and monoclonal anti-her2 antibodies as antitumors agents |
PL217410B1 (en) | 2000-05-19 | 2014-07-31 | Genentech Inc | Gene detection assay for improving the likelihood of an effective response to an erbb antagonist cancer therapy |
WO2002045653A2 (en) | 2000-12-08 | 2002-06-13 | Uab Research Foundation | Combination radiation therapy and chemotherapy in conjuction with administration of growth factor receptor antibody |
SK9072003A3 (en) | 2001-01-09 | 2003-11-04 | Merck Patent Gmbh | Combination therapy using receptor tyrosine kinase inhibitors and angiogenesis inhibitors |
JP5069843B2 (en) | 2002-07-15 | 2012-11-07 | ジェネンテック, インコーポレイテッド | Method for identifying tumors responsive to treatment with anti-ErbB2 antibodies |
US20040258685A1 (en) | 2002-11-21 | 2004-12-23 | Genentech, Inc. | Therapy of non-malignant diseases or disorders with anti-ErbB2 antibodies |
JP4969440B2 (en) | 2004-04-08 | 2012-07-04 | デビッド, ビー. エイガス, | ErbB antagonist for the treatment of pain |
SV2006002143A (en) | 2004-06-16 | 2006-01-26 | Genentech Inc | USE OF AN ANTIBODY FOR THE TREATMENT OF CANCER RESISTANT TO PLATINUM |
US7560111B2 (en) | 2004-07-22 | 2009-07-14 | Genentech, Inc. | HER2 antibody composition |
JO3000B1 (en) | 2004-10-20 | 2016-09-05 | Genentech Inc | Antibody Formulations. |
CN101115849A (en) | 2004-12-07 | 2008-01-30 | 健泰科生物技术公司 | Selecting patients for therapy with a her inhibitor |
CN102580084B (en) | 2005-01-21 | 2016-11-23 | 健泰科生物技术公司 | The fixed dosage of HER antibody is administered |
CN103251946A (en) * | 2005-02-23 | 2013-08-21 | 健泰科生物技术公司 | Extending time to disease progression or survival in cancer patients using a her dimerization inhibitor |
US20060204505A1 (en) | 2005-03-08 | 2006-09-14 | Sliwkowski Mark X | Methods for identifying tumors responsive to treatment with HER dimerization inhibitors (HDIs) |
JP2006316040A (en) * | 2005-05-13 | 2006-11-24 | Genentech Inc | Herceptin(r) adjuvant treatment |
PE20070207A1 (en) | 2005-07-22 | 2007-03-09 | Genentech Inc | COMBINED TREATMENT OF TUMORS THAT EXPRESS HER |
US7700299B2 (en) | 2005-08-12 | 2010-04-20 | Hoffmann-La Roche Inc. | Method for predicting the response to a treatment |
TW200812615A (en) | 2006-03-22 | 2008-03-16 | Hoffmann La Roche | Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2 |
WO2007145862A2 (en) | 2006-06-05 | 2007-12-21 | Genentech, Inc. | Extending survival of cancer patients with elevated levels of egf or tgf-alpha |
JP5317084B2 (en) | 2006-11-08 | 2013-10-16 | 国立大学法人愛媛大学 | π-conjugated cyclic compound and process for producing the same |
WO2008109440A2 (en) * | 2007-03-02 | 2008-09-12 | Genentech, Inc. | Predicting response to a her dimerisation inhibitor based on low her3 expression |
JP5117165B2 (en) | 2007-11-09 | 2013-01-09 | 花王株式会社 | Method for producing oil-in-water emulsion composition |
JP5170667B2 (en) | 2008-06-02 | 2013-03-27 | 小林クリエイト株式会社 | Information hiding form |
BRPI0812682A2 (en) * | 2008-06-16 | 2010-06-22 | Genentech Inc | metastatic breast cancer treatment |
JP5213775B2 (en) | 2009-03-25 | 2013-06-19 | 株式会社ジャパンディスプレイウェスト | Electro-optical device and electronic apparatus |
-
1998
- 1998-12-07 ZA ZA9811162A patent/ZA9811162B/en unknown
- 1998-12-10 CA CA2311409A patent/CA2311409C/en not_active Expired - Lifetime
- 1998-12-10 DK DK98963840.8T patent/DK1037926T3/en active
- 1998-12-10 IL IL13620198A patent/IL136201A0/en unknown
- 1998-12-10 KR KR1020007006372A patent/KR20010033019A/en not_active Application Discontinuation
- 1998-12-10 TR TR2000/01689T patent/TR200001689T2/en unknown
- 1998-12-10 EP EP98963840.8A patent/EP1037926B1/en not_active Revoked
- 1998-12-10 KR KR1020147035850A patent/KR20150013870A/en not_active Application Discontinuation
- 1998-12-10 EP EP10177992A patent/EP2275450A1/en not_active Withdrawn
- 1998-12-10 US US09/208,649 patent/US7846441B1/en not_active Expired - Fee Related
- 1998-12-10 CA CA2730373A patent/CA2730373A1/en not_active Abandoned
- 1998-12-10 ES ES98963840.8T patent/ES2450922T3/en not_active Expired - Lifetime
- 1998-12-10 EP EP10178009A patent/EP2277919A1/en not_active Ceased
- 1998-12-10 WO PCT/US1998/026266 patent/WO1999031140A1/en active Application Filing
- 1998-12-10 KR KR1020087018921A patent/KR20080075042A/en not_active Application Discontinuation
- 1998-12-10 CN CN200610008639XA patent/CN1820734B/en not_active Ceased
- 1998-12-10 KR KR1020127013045A patent/KR20120062942A/en not_active Application Discontinuation
- 1998-12-10 CN CNB988120976A patent/CN1269839C/en not_active Expired - Lifetime
- 1998-12-10 KR KR1020107028433A patent/KR20100135337A/en not_active Application Discontinuation
- 1998-12-10 KR KR1020187027274A patent/KR20180107323A/en not_active Application Discontinuation
- 1998-12-10 AU AU19081/99A patent/AU1908199A/en not_active Abandoned
- 1998-12-10 KR KR1020137005286A patent/KR20130036367A/en not_active Application Discontinuation
- 1998-12-10 JP JP2000539062A patent/JP2002508397A/en not_active Withdrawn
- 1998-12-10 BR BR9815363-3A patent/BR9815363A/en not_active Application Discontinuation
- 1998-12-11 AR ARP980106308A patent/AR020051A1/en unknown
-
2000
- 2000-05-17 NZ NZ504597A patent/NZ504597A/en not_active IP Right Cessation
- 2000-05-17 IL IL136201A patent/IL136201A/en not_active IP Right Cessation
- 2000-06-09 NO NO20002957A patent/NO20002957L/en unknown
-
2001
- 2001-03-06 HK HK01101597.4A patent/HK1030784A1/en not_active IP Right Cessation
-
2003
- 2003-02-03 US US10/356,824 patent/US7892549B2/en not_active Expired - Fee Related
- 2003-04-04 US US10/406,925 patent/US20030170234A1/en not_active Abandoned
-
2004
- 2004-08-02 US US10/909,998 patent/US8642036B2/en not_active Expired - Lifetime
-
2006
- 2006-10-27 HK HK06111909.1A patent/HK1091391A1/en not_active IP Right Cessation
-
2007
- 2007-07-20 US US11/780,640 patent/US8075892B2/en not_active Expired - Fee Related
-
2008
- 2008-01-04 US US11/969,465 patent/US20080187533A1/en not_active Abandoned
-
2009
- 2009-03-17 NO NO20091147A patent/NO20091147L/en not_active Application Discontinuation
-
2010
- 2010-04-07 JP JP2010088515A patent/JP2010209081A/en active Pending
-
2011
- 2011-05-09 US US13/103,799 patent/US8309087B2/en not_active Expired - Fee Related
- 2011-07-14 IL IL214084A patent/IL214084A/en not_active IP Right Cessation
- 2011-07-18 US US13/185,329 patent/US8425908B2/en not_active Expired - Fee Related
-
2012
- 2012-10-04 JP JP2012222108A patent/JP2013056887A/en not_active Withdrawn
-
2013
- 2013-03-15 US US13/841,146 patent/US20130209459A1/en not_active Abandoned
- 2013-12-26 US US14/141,232 patent/US20140341886A1/en not_active Abandoned
-
2014
- 2014-09-17 IL IL234696A patent/IL234696A/en not_active IP Right Cessation
-
2015
- 2015-06-09 JP JP2015116874A patent/JP2016006046A/en not_active Withdrawn
-
2016
- 2016-09-23 JP JP2016185281A patent/JP2017039737A/en active Pending
-
2017
- 2017-04-05 JP JP2017075241A patent/JP2017165737A/en not_active Withdrawn
-
2018
- 2018-12-05 JP JP2018227941A patent/JP2019055979A/en active Pending
-
2019
- 2019-04-23 US US16/392,300 patent/US20190240185A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2311409A1 (en) | Treatment with anti-erbb2 antibodies | |
Herbst et al. | IMC-C225, an anti-epidermal growth factor receptor monoclonal antibody for treatment of head and neck cancer | |
Tijink et al. | Radioimmunotherapy of head and neck cancer xenografts using 131I-labeled antibody L19-SIP for selective targeting of tumor vasculature | |
Gong et al. | Growth inhibitory effects of trastuzumab and chemotherapeutic drugs in gastric cancer cell lines | |
Fabbrini et al. | Selective occlusion of tumor blood vessels by targeted delivery of an antibody‐photosensitizer conjugate | |
Lee et al. | EphA2 immunoconjugate as molecularly targeted chemotherapy for ovarian carcinoma | |
Merlin et al. | In vitro comparative evaluation of trastuzumab (Herceptin®) combined with paclitaxel (Taxol®) or docetaxel (Taxotere®) in HER2-expressing human breast cancer cell lines | |
Barginear et al. | Trastuzumab-DM1: a clinical update of the novel antibody-drug conjugate for HER2-overexpressing breast cancer | |
Lee et al. | Enhanced efficacy of radioimmunotherapy with 90Y-CHX-A ″-DTPA-hu3S193 by inhibition of epidermal growth factor receptor (EGFR) signaling with EGFR tyrosine kinase inhibitor AG1478 | |
Kok et al. | Expression of Cyr61 (CCN1) in human oral squamous cell carcinoma: An independent marker for poor prognosis | |
US20130273031A1 (en) | Novel anti-igf-ir antibodies and uses thereof | |
WO2002045653A3 (en) | Combination radiation therapy and chemotherapy in conjuction with administration of growth factor receptor antibody | |
Georgieva et al. | ZM447439, a novel promising aurora kinase inhibitor, provokes antiproliferative and proapoptotic effects alone and in combination with bio-and chemotherapeutic agents in gastroenteropancreatic neuroendocrine tumor cell lines | |
IL140138A0 (en) | Specific antibodies of tie-2 ligands | |
HUP0102992A3 (en) | Antibodies to the ed-b domain of fibronectin, conjugates containing them and use therefor for diagnosis and therapy of tumors and diseases associated with angiogenesis | |
Hansel et al. | Expression of the caudal-type homeodomain transcription factors CDX 1/2 and outcome in carcinomas of the ampulla of Vater | |
Gholam et al. | Combined paclitaxel and cetuximab achieved a major response on the skin metastases of a patient with epidermal growth factor receptor-positive, estrogen receptor-negative, progesterone receptor-negative and human epidermal growth factor receptor-2-negative (triple-negative) breast cancer | |
Wood et al. | Initial testing (Stage 1) of the antibody‐maytansinoid conjugate, IMGN901 (Lorvotuzumab mertansine), by the pediatric preclinical testing program | |
JP2008504226A (en) | Cancer disease modifying antibodies | |
Modjtahedi | Molecular therapy of head and neck cancer | |
Rait et al. | HER‐2‐targeted antisense oligonucleotide results in sensitization of head and neck cancer cells to chemotherapeutic agents | |
Takahashi et al. | HER2 targeting near‐infrared photoimmunotherapy for a CDDP‐resistant small‐cell lung cancer | |
Van Gog et al. | Perspectives of combined radioimmunotherapy and anti‐EGFR antibody therapy for the treatment of residual head and neck cancer | |
NO985904D0 (en) | TIE-2 receptor ligands (TIE-ligand-3, TIE-ligand-4), and use thereof | |
Chung et al. | PI3K inhibitors in trastuzumab-resistant HER2-positive breast cancer cells with PI3K pathway alterations |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKEX | Expiry |
Effective date: 20181210 |